NMS·Healthcare·$182M·#300 / 520 in Healthcare
PYXS Pyxis Oncology, Inc.
39HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY60
STABILITY27
VALUATION34
GOVERNANCE81
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-14.2%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
82.8%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
3 months
5
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
35.0%
70
< 25% strong
Price / Sales
Market cap relative to trailing revenue
13.1x
34
< 3x strong
Rule of 40
Growth rate plus operating margin
-623
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
17.8%
81
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+2.8%
83
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE PYXS WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when PYXS's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.